Huntington’s disease and Alzheimer’s disease are both progressive, fatal neurodegenerative conditions, but they differ in nearly every meaningful way: the genes that cause them, the age they strike, the brain regions they destroy first, and the symptoms that show up earliest. Huntington’s is driven by a single inherited mutation and typically announces itself with movement problems and personality changes in midlife, while Alzheimer’s usually emerges after age 65 and begins with memory loss. Understanding these differences matters for diagnosis, treatment decisions, family planning, and the daily reality of living with or caring for someone who has either disease.
How the Genetics Differ
Huntington’s disease is one of the clearest examples of a single-gene disorder in neurology. It results from an expanded stretch of CAG repeats in the HTT gene: anyone who inherits 36 or more repeats will develop the disease, and each child of an affected parent has a 50 percent chance of inheriting the mutation.1PubMed Central. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup This means Huntington’s follows a straightforward autosomal-dominant inheritance pattern. If you carry the mutation, you will get the disease. The only question is when.
Alzheimer’s genetics are far messier. A small fraction of cases, usually striking before age 65, are caused by rare mutations in the APP, PSEN1, or PSEN2 genes. These familial forms behave much like Huntington’s in that a single mutation virtually guarantees the disease. But the vast majority of Alzheimer’s cases are late-onset and sporadic, meaning no single gene is responsible. The strongest genetic risk factor for the common form is the APOE ε4 variant, which raises risk substantially but does not make the disease inevitable.2PubMed. A Comprehensive Review of Genetic Risk Factors for Alzheimer’s Disease Development Carrying one copy of APOE ε4 roughly triples your risk; carrying two copies raises it further. But many carriers never develop Alzheimer’s, and many people who get it carry no copies at all. Dozens of other genetic variants contribute small amounts of additional risk.
This genetic difference has enormous practical consequences. A blood test or saliva sample can tell someone with certainty whether they carry the Huntington’s mutation. Alzheimer’s genetic testing, by contrast, gives you a probability, not a verdict. That distinction shapes everything from family planning conversations to the psychological weight of a test result.
When Each Disease Typically Appears
Huntington’s disease is unusual among dementias in how early it tends to appear. In a study of young-onset dementia patients, those with Huntington’s had the youngest average age of onset at about 44 years, significantly younger than patients with other dementia subtypes.3PubMed Central. Survival in Huntington’s disease and other young‐onset dementias Some people develop symptoms in their twenties or thirties (juvenile Huntington’s), while others may not show signs until their sixties, but the typical window is the late thirties to mid-forties. The number of CAG repeats partly determines timing: more repeats generally means earlier onset.
Alzheimer’s overwhelmingly affects people over 65. The risk roughly doubles every five years after that threshold. Early-onset Alzheimer’s, caused by those rare APP, PSEN1, or PSEN2 mutations, can appear as early as the thirties or forties, but it accounts for a small fraction of total cases. For most families, Alzheimer’s is a disease of old age, while Huntington’s disrupts lives during what should be peak working and parenting years.
Which Parts of the Brain Are Hit First
One of the starkest contrasts between these diseases is where in the brain the damage begins. In Huntington’s, the primary target is the striatum, a deep brain structure involved in movement coordination, habit learning, and emotional regulation. Within the striatum, medium spiny neurons are selectively vulnerable, dying off despite the fact that the huntingtin protein is expressed throughout the brain.4Neurotherapeutics. Huntington’s Disease and the Striatal Medium Spiny Neuron: Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Disease Research in mouse models has linked this vulnerability to disrupted calcium signaling: in mice carrying the Huntington’s mutation, repeated exposure to the neurotransmitter glutamate drives abnormal calcium buildup in these neurons, triggering cell death.5PubMed Central. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington’s disease
Alzheimer’s follows a different trajectory. The disease is defined by the accumulation of two abnormal proteins: amyloid-beta plaques and tau tangles. These spread through the brain in characteristic patterns, though the exact sequence varies between individuals. Research using neuropathology data has identified at least two subtypes: one in which amyloid plaques spread through the cortex first and tau tangles follow, and another in which tau appears early in memory-critical regions like the entorhinal cortex and hippocampus before amyloid plaques become widespread.6Brain. A data-driven study of Alzheimer’s disease related amyloid and tau pathology progression Either way, the hippocampus and entorhinal cortex, the brain’s core memory-formation circuitry, sustain early and severe damage. That is why memory loss dominates the clinical picture.
The Symptoms That Show Up First
Huntington’s disease is sometimes described as a triad of motor, cognitive, and psychiatric symptoms, and all three domains can be affected from very early on. The motor symptoms most people associate with Huntington’s are involuntary, dance-like movements called chorea. But the picture shifts with age of onset: younger patients tend to show more rigidity and dystonia (sustained muscle contractions) and less chorea, while also experiencing faster overall decline.7PubMed. Huntington’s disease: clinical correlates of disability and progression Beyond chorea, patients develop difficulty with voluntary movements like walking, swallowing, and speaking. These motor problems are often what leads to diagnosis, but they are rarely the first thing that goes wrong.
Alzheimer’s earliest and most recognizable symptom is difficulty forming new memories. You forget a conversation that happened an hour ago. You repeat the same question. You lose track of appointments. As the disease progresses, other cognitive abilities erode: language, spatial navigation, the ability to plan and execute tasks. Motor symptoms do occur in Alzheimer’s, including gait disturbances, muscle weakness, and balance problems, but these are traditionally associated with more advanced stages.8PubMed Central. Alzheimer’s Disease: Understanding Motor Impairments Emerging evidence suggests some subtle motor changes may appear earlier than previously recognized, but they are rarely the symptom that brings someone to the doctor.
How Thinking Breaks Down Differently
Neuropsychologists have historically distinguished between “cortical” and “subcortical” patterns of cognitive decline, and Huntington’s and Alzheimer’s sit on opposite sides of that divide. Huntington’s produces deficits rooted in disrupted connections between the frontal cortex and the striatum. People with Huntington’s struggle most with delayed recall, learning new information, mental flexibility, and abstract thinking, while verbal skills tend to be relatively preserved until later stages.9PubMed. The subcortical dementia of Huntington’s disease The problem is less about storage of memories and more about retrieval and executive control: a Huntington’s patient may know the answer but have trouble accessing it on demand.
Alzheimer’s attacks memory consolidation itself. The neuron loss in the entorhinal cortex, a gateway structure feeding information into the hippocampus, is specific to Alzheimer’s and directly accounts for the hallmark difficulty in forming new episodic memories.10PubMed Central. Episodic memory on the path to Alzheimer’s disease The information never gets properly encoded in the first place, which is why recognition cues and prompts are less helpful than they can be in Huntington’s. Over time, Alzheimer’s also impairs language, visuospatial skills, and the ability to recognize familiar objects or faces. But memory consolidation problems are often the prototypical and earliest feature.11PubMed Central. Episodic memory and associated cortical atrophy in amnestic early-onset and late-onset Alzheimer’s disease
Psychiatric and Behavioral Changes
Both diseases produce psychiatric symptoms, but the timing and character differ. In Huntington’s, psychiatric changes frequently precede the motor symptoms by years. Apathy is present in roughly a third of people who carry the mutation but have not yet been formally diagnosed, rising to about two-thirds in early-stage disease. Irritability and executive dysfunction also emerge well before motor onset.12PubMed. Neuropsychiatric symptoms are very common in premanifest and early stage Huntington’s Disease Irritability in Huntington’s can be especially disruptive, manifesting as abrupt and unpredictable outbursts of anger that strain relationships and make daily life volatile.13PubMed Central. Irritability in Huntington’s Disease Depression is another common feature, with its prevalence peaking in early manifest disease while also appearing during the prodromal period before motor symptoms begin.14PubMed Central. Depression in the early stages of Huntington disease
Alzheimer’s produces its own set of behavioral disturbances, though they tend to emerge later in the disease course. Agitation, anxiety, wandering, and suspiciousness are common in moderate-to-advanced stages. A distinctive behavioral pattern in Alzheimer’s is sundowning syndrome, in which confusion, agitation, and other behavioral problems intensify in the late afternoon and evening. Research has linked sundowning to dysregulation of stress hormone pathways and found that exercise-based treatments can reduce both cortisol levels and behavioral symptoms by roughly half.15PubMed. Effectiveness of Exercise- and Cognitive-Based Treatments on Salivary Cortisol Levels and Sundowning Syndrome Symptoms in Patients with Alzheimer’s Disease While apathy occurs in both diseases, the explosive irritability characteristic of Huntington’s is less typical of Alzheimer’s, where apathy more often presents as a quiet withdrawal from activities and social engagement.
How Each Disease Is Diagnosed
Huntington’s diagnosis can be made with near-absolute certainty through a genetic test. If someone with a family history of the disease develops motor or psychiatric symptoms and a blood test shows 36 or more CAG repeats in the HTT gene, the diagnosis is confirmed. Predictive testing is also available for at-risk family members who have no symptoms yet, though many people choose not to take it. Brain imaging in Huntington’s typically shows atrophy of the caudate nucleus within the striatum, and changes in brain connectivity can be detected even before symptoms appear. Research has found altered default-mode network connectivity in people carrying the mutation who have not yet developed clinical disease.16PubMed. Default-mode network changes in preclinical Huntington’s disease
Alzheimer’s diagnosis has historically relied on clinical evaluation: a physician documents progressive memory loss, rules out other causes, and makes a probable diagnosis. Definitive confirmation traditionally required autopsy. That has changed with the development of biomarker-based approaches. Amyloid PET scanning can detect amyloid plaques in living patients, and a framework proposed by the National Institute on Aging now defines Alzheimer’s based purely on biomarker status: the presence of abnormal amyloid and tau, regardless of symptoms.17Journal of Nuclear Medicine. The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review Blood-based biomarker tests for amyloid and tau are also becoming available, making earlier and more accurate diagnosis possible outside specialized research centers.
Treatment Options and Research Frontiers
Neither disease has a cure, but the treatment landscapes look quite different. For Huntington’s, the only approved pharmacological treatments target the motor symptom of chorea: tetrabenazine and deutetrabenazine, which work by reducing dopamine signaling.18PubMed Central. New directions in therapeutics for Huntington disease No approved therapy slows the underlying progression. The most promising experimental strategies aim to lower levels of the toxic mutant huntingtin protein itself. These include antisense oligonucleotides (short pieces of engineered DNA that block the gene’s message), CRISPR-based gene editing, and small molecules designed to trigger destruction of the mutant protein.19PubMed Central. Therapeutic strategies for Huntington’s disease: current approaches and future direction Early clinical trials of huntingtin-lowering antisense oligonucleotides showed they could reduce levels of the mutant protein in cerebrospinal fluid, though later-stage trials have had setbacks.20PubMed. Recent advances in the therapeutic development for Huntington disease
Alzheimer’s treatment has traditionally relied on drugs that modestly boost brain signaling, such as cholinesterase inhibitors and memantine. These do not alter the disease course but can temporarily ease symptoms. A newer class of drugs, anti-amyloid monoclonal antibodies, represents the first treatments designed to remove amyloid plaques from the brain. A meta-analysis found that these antibodies slowed cognitive decline on standard rating scales compared to placebo, while older cholinesterase inhibitors did not show the same effect on those measures. However, the benefits, while statistically detectable, remained below the threshold researchers typically consider clinically meaningful for individual patients.21PubMed Central. The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis Whether that small average slowing translates into noticeable benefit for any given person remains actively debated.
Survival and Disease Trajectory
Both diseases are ultimately fatal, but the timelines differ. In a study comparing young-onset dementia subtypes, Huntington’s patients had the longest median survival at about 19 years from onset, compared to roughly 11 years for Alzheimer’s patients in the same age bracket.3PubMed Central. Survival in Huntington’s disease and other young‐onset dementias That comparison involves young-onset cases of both diseases, so the Alzheimer’s patients in that study were unusually young. For typical late-onset Alzheimer’s, average survival after diagnosis is commonly cited as eight to twelve years, though it varies widely based on age at diagnosis and overall health.
The trajectory also feels different day to day. Huntington’s involves a slow, relentless deterioration across motor, cognitive, and psychiatric domains simultaneously. People gradually lose the ability to work, drive, manage finances, and eventually eat and communicate. Alzheimer’s decline tends to be more stepwise and cognitively focused in early and middle stages, with physical function relatively preserved until later. Both diseases eventually lead to total dependence on caregivers.
The Caregiver Experience
Caring for someone with either disease is extraordinarily demanding, but the specific burdens differ. In Huntington’s, the combination of behavioral volatility, physical decline, and cognitive loss creates a particularly complex caregiving situation. A longitudinal study of Huntington’s caregiver-patient pairs identified distinct clusters: patients with advanced disease and high levels of irritability and obsessive-compulsive behaviors placed a high and increasing burden on their caregivers, while those whose advanced disease was dominated by apathy actually showed decreasing caregiver burden over time. Even among patients in earlier stages, rising depression scores predicted increasing caregiver strain.22PubMed Central. The burden of Huntington’s disease: A prospective longitudinal study of patient/caregiver pairs The irritability and anger outbursts characteristic of Huntington’s can be more immediately distressing for family members than the gradual memory loss of Alzheimer’s, even though Alzheimer’s caregiving carries its own heavy toll of grief, exhaustion, and social isolation.
Huntington’s caregivers also face the additional psychological weight of genetic certainty: if their partner or parent has it, their children may carry the mutation. Alzheimer’s caregivers rarely face the same degree of genetic determinism, since most Alzheimer’s is not caused by a single inherited gene.
What Is Happening Inside the Cells
At a cellular level, the two diseases involve overlapping but distinct mechanisms of damage. In Huntington’s, the mutant huntingtin protein disrupts mitochondria, the structures that produce energy inside cells. It interferes with a key regulatory molecule called PGC-1α, making neurons more susceptible to oxidative stress and impairing the cell’s ability to manage its energy supply, calcium balance, and waste cleanup.23PubMed. Mitochondrial Dysfunction in Huntington’s Disease: Pathogenesis and Therapeutic Opportunities These disruptions occur in presymptomatic stages, meaning the cellular machinery is breaking down well before a person notices anything wrong.
Alzheimer’s cellular pathology centers on the buildup of amyloid and tau proteins, but the brain’s immune response plays a major role in determining how much damage those proteins cause. Microglia, the brain’s resident immune cells, are supposed to clear debris and damaged proteins. A receptor on microglia called TREM2 has emerged as a critical player: mutations in TREM2 are genetic risk factors for sporadic Alzheimer’s, and the receptor appears to influence how effectively microglia respond to both amyloid and tau pathology.24PubMed Central. TREM2 Mediates Microglial Anti-Inflammatory Activations in Alzheimer’s Disease: Lessons Learned from Transcriptomics In animal models, antibodies that activate TREM2 have been shown to boost microglial activity around amyloid plaques and improve cognitive function, pointing toward a potential therapeutic angle.25PubMed Central. Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimer’s disease models Neuroinflammation matters in Huntington’s too, but the primary insult is the toxic protein itself rather than a failure of the brain’s cleanup systems.
Huntington’s as a Neurodevelopmental Disease
One of the more surprising recent findings is that Huntington’s disease may not be purely a degenerative condition. Examination of brain tissue from human fetuses carrying the Huntington’s mutation (at 13 weeks of gestation) revealed clear abnormalities in cortical development, including defects in how neural progenitor cells divide, orient, and differentiate.26PubMed Central. Huntington’s disease alters human neurodevelopment The brain may be built slightly differently from the very start in people who carry the mutation, with degeneration layered on top of a subtly altered foundation decades later. This neurodevelopmental dimension has no parallel in Alzheimer’s, which is understood entirely as a disease of aging even in its early-onset genetic forms. It also raises the question of whether some of the cognitive and psychiatric features of Huntington’s that appear before diagnosis reflect longstanding differences in brain wiring rather than early degeneration.
Genetic Testing and the Ethics of Knowing
The availability of definitive predictive genetic testing for Huntington’s creates dilemmas that do not arise in the same way for Alzheimer’s. A person in their twenties with a parent who has Huntington’s can find out with certainty whether they will develop the disease, potentially decades before any symptoms appear. There is no treatment to offer them if the result is positive, and the psychological impact of that knowledge is substantial. Genetic counseling protocols for Huntington’s testing are among the most carefully structured in medicine, typically involving multiple sessions over weeks or months.
Alzheimer’s genetic testing raises different concerns. APOE genotyping and newer polygenic risk scores can estimate probability, but they do not deliver certainty. Communicating probabilistic risk is inherently harder than communicating a deterministic result, and people may over- or underestimate what a given risk score means. Both conditions share challenges around informed consent, potential for genetic discrimination, and the psychological burden of knowing you face a disease with no cure.27PubMed. Genetic testing for neurodegenerative diseases: Ethical and health communication challenges Direct-to-consumer genetic testing kits have made APOE results available to anyone who orders one, sometimes without adequate context for interpreting the results, a situation that genetic counselors have repeatedly flagged as problematic.